Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome.

doi:10.1002/cpt.2013

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome.

Clinical pharmacology and therapeutics - 1 Feb 2021

Ruiz-Pinto Sara, Pita Guillermo, Martín Miguel, Nuñez-Torres Rocío, Cuadrado Ana, Shahbazi Marta N, Caronia Daniela, Kojic Alexander, Moreno Leticia T, de la Torre-Montero Julio C, Lozano María, López-Fernández Luis A, Ribelles Nuria, García-Saenz Jose A, Alba Emilio, Milne Roger L, Losada Ana, Pérez-Moreno Mirna, Benítez Javier, González-Neira Anna

Abstract excerpt

Capecitabine-induced hand-foot syndrome (CiHFS) is a common dermatological adverse reaction affecting around 30% of patients with capecitabine-treated cancer, and the main cause of dose reductions and chemotherapy delays. To identify novel genetic factors associated with CiHFS in patients with cancer, we carried out an extreme-phenotype genomewide association study in 166 patients with breast and colorectal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cadherins

Share to Capecitabine

Share to Cell Line

Share to Keratinocytes

Share to Neoplasms

Share to Promoter Regions, Genetic

Share to Risk

Source

Open in PubMed

Identifiers

PMID: 32757270
DOI: 10.1002/cpt.2013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome.PMID 32757270Read ↗

A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.Semantic proximity Read ↗

Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYDSemantic proximity Read ↗

Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.Semantic proximity Read ↗

Polymorphisms of FGFR Pathway-related Factors and Capecitabine-induced Hand-foot Syndrome in Japanese Patients With Colorectal Cancer.Semantic proximity Read ↗

Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.Semantic proximity Read ↗

Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.Semantic proximity Read ↗

SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.Semantic proximity Read ↗

Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.Semantic proximity Read ↗

Polymorphisms of MTHFR and TYMS predict capecitabine‐induced hand‐foot syndrome in patients with metastatic breast cancerSemantic proximity Read ↗

Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer.Semantic proximity Read ↗

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.